Fenwick represented Chinook Therapeutics, Inc. (NASDAQ: KDNY), a clinical-stage biotechnology company developing precision medicines for kidney diseases, in its strategic collaboration with Evotec SE focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases.
Based on Evotec’s proprietary comprehensive molecular datasets, Chinook and Evotec will jointly identify, characterize and validate novel mechanisms and discover precision medicines for PKD, lupus nephritis, IgA nephropathy and other primary glomerular diseases. The collaboration will also involve programs currently in Chinook’s clinical and preclinical pipeline.
Under the terms of the agreement, Chinook and Evotec will share drug discovery and preclinical development responsibilities. Chinook will be responsible for clinical development and commercialization of product candidates. Evotec will receive an undisclosed upfront payment, research funding, progress-dependent milestone payments and tiered royalties on net sales for targets. More information can be obtained from Chinook’s announcement.
The Fenwick transaction team was led by life sciences partner Stefano Quintini and included law clerk Kehl Sink.